June 2026 update

The text of the update Zhittya sent, word for word. Pictures, charts and layout are in the PDF. Open the PDF.

June 17, 2026 Monthly Update

Important:

Washington DC: June 23 – 29, 2026: Vika and I will be in Washington DC for a series of important meetings. If you are in the DC area and have a good reason to meet with us, please let me know and Vika and I will try to see you.

Email: dan333@aol.com

FreedomFest: July 9 – 11, 2026 in Las Vegas. Zhittya is sponsoring a dinner on Friday, July 10th for “The Freedom to Try Medical Innovations in Nevada.” This is part of Zhittya’s effort to advance “The Freedom to Try Medical Innovations” Nevada Constitutional Ballot Initiative, thereby enhancing medical discoveries. The Lt. Governor of Nevada, Stavros Anthony, will be speaking, along with some other dignitaries. I will be showing the medical breakthroughs we are advancing already and introducing more on how the Freedom to Try makes life better for everyone. For tickets for the entire FreedomFest go to: https://freedomfest.swoogo.com/vegas2026

For just the dinner go to: https://freedomfest.swoogo.com/zhittya2026 Zhittya’s Complementary Dinner Tickets:

Zhittya has 50 dinner tickets available for our supporters (shareholders, investors, patients) if you wish to be considered, please email: sergiy@zhittyamedicine.com

Chronic Pain: Can FGF-1 Reverse It?

With almost every Monthly Update, I talk about a new idea for applying FGF-1 to treat a new medical indication. Chronic pain is reported to affect over 50 million Americans and worldwide, over a billion people, and “High-Impact Pain”, is pain that frequently restricts daily life and that is estimated to affect over 17 million American adults. Chronic pain is a major unmet medical need!

Why is Zhittya now pursuing an FGF-1 treatment for chronic pain?

Zhittya has dosed over 250 people with Parkinson’s disease and about 80 people in our Medical Research Study to reverse type-2 diabetes. We have received comments from people who were dosed with FGF-1 for their Parkinson’s disease and/or type-2 diabetes, and some of those people also suffered with chronic pain (normally in their feet, neuropathy). Several have reported to us that the pain in their feet has reduced or stopped completely. This unexpected hint that FGF-1 was reducing or eliminating pain, has become too common of an event for us not to study the following question: Chronic Pain, Can FGF-1 Reverse it?

On June 1, 2026, Zhittya treated a Type-2 Diabetes medical research patient for his disease. I will call him Gary. Gary discussed that besides his type-2 diabetes he had pain in his feet and the pain was rising up his left leg and he believed the pain was also moving up his left side as well. We have reported to you in the past that we’ve tried injecting FGF-1 into the feet of people who reported pain in that area of their bodies. That approach did not work. Those patients did not report less pain in their feet after dosing. Between our Parkinson’s disease patients and type- 2 diabetics, we had maybe 7 to 10 patients who had reported that their foot pain was less or no longer there after dosing FGF-1 up their nose. I had assumed that maybe the FGF-1 had rejuvenated the neurons in the area of the brain which reported that pain. When people reported their pain had stopped, I assumed maybe the problem was in the brain, reporting pain that was not actually there, similar to phantom pain. With Gary, what I was thinking no longer made sense. If the pain is not from the foot and not from the brain, what is left? It must be the nerves that travel from the foot to the brain. Question: Is there such a thing as nerve dysfunction? The answer is Yes!

The possibility that FGF-1 can reduce or possibly stop chronic pain is too important to ignore. Zhittya has conducted an AI-powered medical search on

“Can FGF-1 treat chronic pain?” Hundreds of pages of material have been found which say: Yes, in theory and in animal models, FGF-1 could reduce pain. But it also states: “however there has been no human data created to verify that”.

Acute Pain: Most all of us know acute pain; it is short term and usually the result of an injury to the body; we cut a finger, we burn our hands, we fall and break something. Normally, the pain will go away when the damaged area has healed.

Chronic Pain: This type of pain, which can last for months, years, or even for the rest of your life, occurs when an injury to the body is not obvious. Diabetic neuropathy, spinal cord pain, chronic migraines, and more are examples of chronic pain. In investigating chronic pain, I was introduced to a new concept: nerve dysfunction. What is Nerve Dysfunction?

Nerve dysfunction is when, at a cellular level, the operational mechanics of the cell do not function properly. Every cell in your body has biological mechanics which allow it to function and perform tasks for the community of your cell’s needs. When a nerve is not functioning properly, the body has a problem. When a nerve cell is dysfunctional, can it be sending pain signals, which are what we refer to as chronic pain? Cellular Level Mechanisms: Repair of Nerves.

Zhittya’s team of researchers has focused upon chronic pain, not on how to mask the pain, as today's pain treatments do, but on how to repair the biological mechanism of a dysfunctional nerve cell. Can we repair each nerve cell's mechanical functions properly and make pain signals stop? Can FGF-1 repair (rejuvenate) nerve cells and thereby decrease pain? I believe the answer is Yes!

Zhittya’s Scientific White Paper on the Question: Chronic Pain: Can FGF-1 Reverse it? Treating Pain at Its Source.

Zhittya’s President Dr. Jack Jacobs, Dr. Robert Odell, MD (a renowned pain specialist), Viktoriya Tamlenova-Montano, and Sergiy Prokofiy Montano have prepared this White Paper for Zhittya. This is the first Medical White Paper that Zhittya has created on treating pain. I believe that over the next ten years, more of these papers will come out as we discover more about how FGF-1 can treat pain.

To obtain a copy of this White Paper entitled: Chronic Pain- Can FGF-1 Reverse It? Treating Pain at Its Source, please go to this link: zgm.care/pain

I strongly recommend you download and read this paper for your health and the health of those you love. I believe the medical science revealed here is amazing. If Zhittya’s FGF-1 can lessen pain and suffering, by repairing stressed nerves on a cellular level, it will be a major medical breakthrough. Read this, as I have learned that when someone you love has vicious chronic pain, and there is nothing you can do to help them, then that is a living hell for everyone!

Zhittya’s Medical Research Study for treating chronic pain.

Since June 2, 2026, the entire Zhittya team has been investigating nerve dysfunction and chronic pain. WOW, lots of data and a tremendous number of answers: Yes, FGF-1 can rejuvenate a nerve cells' biological mechanisms at a cellular level. A Summary of what we found from our AI search

Research that shows that FGF-1 (acidic Fibroblast Growth Factor, or aFGF) can repair and regenerate nerves was first published in 1991.

The seminal paper identifying FGF-1's role in promoting and regenerating damaged axons (specifically in transected sciatic nerves) was authored by Sweetnam et al. and published in 1991.

Following this foundational research, pioneering in vivo studies on the repair of the central nervous system were published in 1996 by H. Cheng, Y. Cao, and L. Olson in the journal Science. Their research proved that FGF-1, combined with peripheral nerve grafts, could successfully bridge complete spinal cord injuries and partially restore hind-limb function in rats. FGF-1 should be able to rejuvenate nerve cells and thereby lessen pain; however, no human studies have been conducted.

What good is an amazing medical discovery if it is never advanced to reach suffering humans? Since 1991, no one has advanced FGF-1 to lessen the pain and suffering of tens of millions of people? In less than two weeks, Zhittya has gathered great data and is now preparing a “Medical Research Study Protocol” to initiate medical research studies to treat patients with FGF-1 for their chronic pain. I hope we can start this Medical Research Study to treat chronic pain within 90 days. To achieve clarity, I believe we will need to do three separate studies, including: (#1) the main chronic pain study, (#2) chronic spinal cord pain and (#3) chronic migraine headaches (which affect around 4 million people in the US, mostly females). How Long does it take FGF-1 to heal nerve cells?

AI answer: FGF-1 (fibroblast growth factor 1, also known as acidic FGF or aFGF) promotes aspects of nerve repair and regeneration, including angiogenesis (new blood vessel growth), neuroprotection, Schwann cell support, axonal sprouting/outgrowth, and remyelination, but there is no single fixed timeline for "remodulating" a dysfunctional nerve.

Nerve remodulation/repair is inherently slow and variable. It depends on factors such as:

• Injury severity/type (e.g., crush vs. transection, acute vs. chronic dysfunction).
• Distance from injury site to target (axons regrow at roughly 1 mm/day or ~1 inch/month in humans; slower/faster in some nerves or animal models).
• Patient age, overall health, comorbidities (e.g., diabetes), and blood supply.
• Delivery method, dose, and sustained availability of FGF-1.

General Nerve Regeneration Timelines

• Early phase (hours to days/weeks): Wallerian degeneration clears debris; growth factors (including endogenous FGFs) spike to support Schwann cells and initial sprouting. Exogenous FGF-1 can accelerate this.
• Axonal growth and bridging: Weeks to months in animal gap models (e.g., 8–24 weeks for significant regeneration across 10–15 mm gaps in rat sciatic nerve studies with FGF-1 conduits).
• Functional recovery/remodulation: Months to years for meaningful sensory/motor improvement, reinnervation, and remyelination. Full recovery is often incomplete, especially in chronic cases or longer distances. Muscle atrophy or end-organ changes can limit outcomes after ~12–18+ months of denervation.

FGF-1 Specific Data from Studies

• Animal models (peripheral nerve injury): In rat sciatic nerve gap repairs using FGF-1-enhanced conduits/gels, improved axonal regeneration, myelinated fiber counts, and functional motor recovery were assessed at 8 weeks (histology/electrophysiology), with further gains or consistent function noted up to 24 weeks. Higher doses (e.g., 10 µg/ml) often matched or approached autograft results. FGF-1 supports early Schwann cell activity and debris clearance.
• Similar timelines appear in other FGF studies (e.g., effects visible in weeks, with sustained benefits over 1–3+ months in delivery systems).
• Zhittya’s FGF-1 studies: Our focus has been more on central nervous system (CNS) applications such as Parkinson’s disease (intranasal delivery), where motor improvements averaged ~54% within 6 months in patient data, alongside fMRI evidence of increased brain blood flow (e.g., 21.2% in one case). This ties into broader regenerative effects (angiogenesis + neurogenesis) that could indirectly support nerve health in conditions involving vascular or ischemic components, such as neuropathy. Preclinical work showed neuron regeneration and functional gains, but peripheral neuropathy-specific human timelines are limited and not prominently detailed in public data.

In short: Initial biological effects (e.g., sprouting, vascular support) can start in days to weeks with proper FGF-1 exposure, but clinically meaningful remodulation of a dysfunctional nerve (improved conduction, sensation, strength) typically requires weeks to several months in optimized models, extending to 6+ months or longer for substantial functional recovery in humans—especially in chronic cases. Sustained or repeated dosing (as in some Zhittya protocols) and combination approaches (e.g., with conduits or other therapies) improve outcomes.

This is based on preclinical and limited clinical data; individual results vary widely, and FGF-1 therapies (particularly for neuropathy) are still investigational in many contexts.

Is FGF-1 transported along nerves?

We know that FGF-1 in the bloodstream has a very short half-life. We and others have studied FGF-1 in the bloodstream, for example, FGF-1 delivered IV (intravenously). Zhittya is now introducing FGF-1 up the nose to travel along the nerves to enter the brain’s cerebral fluids and around the blood-brain barrier. From our research on type-2 diabetes we believe the FGF-1 fixes the “glucose sensing” neurons in the brain, and now we believe FGF-1 may also travel down the nerves into the pancreas and liver. From our recent research, it seems FGF-1 travels along nerves better than through the bloodstream. We have found great data that FGF-1 travels along the nerves and that nerves have many FGF receptors, as those nerves need FGF’s to maintain their cellular mechanics.

Here is a basic map of the nerve highway for transporting FGF-1 around the body. Will Zhittya succeed in reversing chronic pain at a cellular level?

We do not know the answer to this question and that is why it is called discovery. What we do know is we owe a duty to find out. Gary and 17 million Americans, and maybe over 300 million people worldwide, are suffering from “high-impact” chronic pain. Opioids mask the pain but cause horrible side effects. Maybe FGF-1 can alleviate pain by healing the nerve cells. I think fixing the problem at a cellular level is a good thing.

Personal note: My father died from cancer at age 53. He fought in World War II and rose up from absolute poverty to be a brilliant and successful space engineer and businessman. His tolerance for pain, like all real men of the “greatest generation”, was amazing. All my youth, I heard “Men do not cry!” I never saw him cry or complain about pain in his life; until he had dropped from 220 pounds of pure muscle to 75 lbs. of loose skin and bones from cancer eating his body. In his last weeks in the hospital, his pain was so intense that he begged me to kill him and end his suffering. He ordered me to get my gun and shoot him. If I really loved him, he said, please kill me and stop the pain. I did not have the courage to end his suffering, and because of that failure, I am very strongly motivated to find out if our FGF-1 can diminish pain for millions of people who suffer from it every day.

FGF-1's possible ability to lessen chronic pain has been known since 1991, and for 35 years, no one has advanced it. I do not know if FGF-1 will help lessen pain, but what I do know is that we have to find out. Many people complain to me that I take too many things personally; that I should be more professional, dispassionate, and refined. When I fight for the people I love, I take the fight personally. When people are suffering, how can you not take that personally?

In the next several years, we will find out if FGF-1 can reverse chronic pain, and I believe the answer will be yes. Two weeks ago, I had no idea that this pathway to treat chronic pain existed. I thank Gary for being honest with us, and in his efforts to reduce his pain and suffering, he woke up my brain. I cannot tell you Zhittya will succeed, but what I can tell you is that for the millions of chronic pain sufferers, like Gary and my Dad: I will find out. One of the worst times of my life (the weeks my father suffered with vicious pain) is now the driver and fire in my soul. 50 years may have passed since he died, but I feel those horrible moments of him suffering, as if it is happening now. I will not betray that trust. Maybe we can do something to lessen pain. Yes, I take it personally. We will find out if FGF-1 can reverse chronic pain. FDA Status

My friend Steven Moore (who co-authored the book “Trumponomics”) founded the “Unleash Prosperity” organization. In their June 3rd issue, they made the following statement:

Unleash Prosperity Hotline Issue #1526 06/03/2026

1. Faster FDA Approvals Will Save Millions of Lives and Trillions of $$$ We’re happy to report that Fox News covered the latest Unleash Prosperity. A new study on how speeding up drug approvals by opening shorter, alternative pathways to getting safe new drugs on the market would improve and extend millions of lives with trillions in economic benefits.

There is arguably no reform in government that could be more beneficial to the US economy than reducing pain and suffering from disease. And it won’t cost a penny.

President Trump: Please order the FDA to just do it. ______________________________________________ I support Steve’s efforts, and I hope all of you do also. I believe the USA FDA is stopping the creative genius of free market innovation and delaying, destroying, and harming millions of people’s lives. Help us fight this bureaucratic monster, the FDA. Tell your politicians to let biotech entrepreneurs be free, so we can work on the medical problem and not the FDA process problem.

Zhittya’s Medical Research Studies

Medical discovery and studies are expensive. Zhittya is using Medical Research Studies’ funding to advance our medical discoveries. I believe it is an excellent vehicle. We have seen from our Parkinson’s disease patients (and now our type-2 diabetics), that people who have a vested interest in our success are great partners. We have learned much from our Parkinson’s disease patients, because they tell us things that we need to know. I would guess half of the money we have raised for the type-2 diabetes study came from people who have type-2 diabetes and want a better treatment choice than they have now for their health.

Think about it: Zhittya does not want a person who says they will be a test subject in one of our studies, but they want to know how much we are going to pay them. You have a horrible disease, and you want Zhittya to pay you for trying to cure it? Those people have no skin in the game; they easily drop out and have no viable input, because they do not care. Compare that to a couple who have been together for 40 years. They have created 3 lives together (their children) as partners and share a life full of love for each other. One is suffering and the other is caring for their loved one. Who do you think gives us more data? Who do you think demands more results? Everyone at Zhittya will tell you, passionate and involved test subjects give you better data and more details. Who do you think Zhittya wants? If people do not take their health and life personally, I do not want them in our medical research studies. We need and want people who care about the treatment working and helping us find the answers.

Presently, we now have three (3) Medical Research Studies we are funding #1.

No-Option Heart Disease

Heart disease is the leading cause of death in the world.

Zhittya and the Bahamas Heart Centre are conducting a 100-person medical research study to treat no-option heart disease patients with FGF-1, building on three prior successful heart studies. Zhittya is raising $10 million USD to fund this study.

In treating heart disease, we have seen 100% success with zero adverse events across the last 30 years, and I believe the millions of people facing certain death will travel to the Bahamas to save and extend their lives.

If you are interested in learning more about the investment opportunity for the “Small Vessel Heart Disease Medical Research Study” (minimum investment of

$25,000), please email me at Dan333@aol.com or call 702-802-8373. Investment benefits include:

• 50% royalty on Zhittya's revenue for the treatment of small vessel heart disease (up to 10x the original investment).
• Put Option: Receive 2x your original investment after 48 months if you are not happy.

I believe the demand among well-resourced patients to save their own lives will be strong. If heart disease runs in your family, you may be able to invest, earn returns, and benefit your own health and life—and advance medical innovation that could help millions. #2. Chronic Wounds—Diabetic Foot Ulcers (DFUs)

In October 2025, Zhittya announced it would raise $5 million for a Medical Research Study for chronic wounds. Zhittya raised $1 million in a few weeks (out of the $5 million target) for the chronic wounds medical research study. That first million allowed us to move forward and identify an enhanced path to success that I believe will be quicker and more successful.

Zhittya is moving forward with submitting a wound-healing IND application for Phase I studies as quickly as possible.

Now we are pushing to raise more capital (the remaining $4 million) for the Wound Healing Medical Research Study for diabetic foot ulcers, because I believe we could be at the FDA in 2027.

For more information on the DFU program, go to: cure-wounds.com

If you are interested in the Wound Healing investment opportunity (minimum investment of $25,000), email me at Dan333@aol.com or call 702-802-8373. It has the same benefits structure as mentioned above:

• 50% royalty on Zhittya's revenue for wound healing treatments (up to 10x the original investment).
• Put Option: 2x your original investment after 48 months if you are not happy. #3. New Study: A Medical Research Study for Chronic Pain.

In just two weeks, Zhittya has uncovered a treasure trove of data supporting the idea that FGF-1 can repair nerves and thereby perhaps reverse chronic pain. Gary, after just two weeks, says his type-2 diabetes is gone, his pain is reduced, and he wants to invest in a Medical Research Study to explore if FGF-1 can reverse chronic pain for millions of people. Zhittya has not completed the study protocol or obtained the IRB clearance yet for our chronic pain study. IRB stands for Institutional Review Board and is registered with the US Department of Health and Human Services. I hope we will have those clearances within 60 days (not 30 years). Zhittya is launching the funding for its Medical Research Study for Chronic Pain now. Gary is a perfect example of what the world needs, people who in their enlightened Self-Interest are “Patient Funding Medical Research Study” for a disease they care about personally, themselves or a loved one. Gary wants his pain to stop. He is willing to experiment with Zhittya’s FGF-1. He reports the pain in his lower back is reduced after a few weeks after dosing with FGF-1. Is it real or is his mind fooling him? I do not know. What I do know is if Zhittya follows the breadcrumbs, maybe we will learn that answer. If it is Yes, FGF-1 can rejuvenate the nerve cells in the lower back thereby reducing pain for 200 million people, those people will owe Gary a thank you, even if they never meet him.!

Every day, 17 million people in the United States with high-impact pain are suffering. I believe the vast majority want their pain to stop. I have many friends who suffered with chronic back pain, foot neuropathy, or vicious headaches that damaged their lives. I believe people with daily pain will respond to Zhittya’s possible treatment to end their suffering. If only the richest 1% of the 17 million people in the United States with high-impact pain are interested in helping us, that would be approximately 170,000 people. I believe finding and treating the first 100 people in a Zhittya Medical Research Study to reverse chronic pain should fill up fast.

Zhittya’s idea is simple: Investors who want to make money and discover a new medical treatment should join with Zhittya to get the job done. Imagine if 30 years ago, we had obtained clearance to treat chronic pain, how many millions of people might have had a better life? The premise of free-market economics is that those who deliver what people want will make a profit. There can be no profit with no risk-taking and no innovation. Gary is a very successful businessperson, and he is pleased that his personal pain has been reduced in a few weeks. He is a good man who wants to help others suffering from chronic pain, and he sees an opportunity to do good and make money. He and I believe that being able to reverse chronic pain could be an enormous business opportunity.

Zhittya will offer the same 50% royalty of the cash it receives from sales of the medicine for chronic pain until the investor has received back ten times their investment. Zhittya will also give the investor a put option - if they are not happy at 48 months, Zhittya will take back their investment at 2 times their original investment.

I personally believe people suffering with chronic pain are motivated to act to end their suffering. I believe the funding for the Medical Research Study to Reverse Chronic Pain will be taken up quickly. If the United States has 17 million high- impact pain sufferers, it can be estimated that the worldwide number is 20 times higher, or possibly over 340 million people. If the richest 1% of that 340 million, or 3.4 million people who want their pain to stop, I believe Zhittya can obtain the funding to move this project forward quickly. If Zhittya has human data in two years that we can reverse severe back pain in 50% of the patients treated, I believe we will be able to advance quickly toward full regulatory approval. If FGF- 1 continues to show that it is a safe product (as it has for over 30 years) and it reduces severe back pain, I believe the world is a better place.

If you are interested in reversing chronic pain, go and register at: zgm.care/pain

One more personal comment. When I started on the floor of the Los Angeles Stock Exchange in 1968, I was there by 5:30 AM, worked until 4 PM, and then went to university at night from 6 PM to 9 PM. I had many headaches. I took headache medicine all the time. When Zhittya patients told us their headaches had reduced or stopped, I did not think about it. When people who experienced migraine headaches told us their headaches were reduced or stopped, I did not associate that with anything. When we started this research into nerve pain, and after I read so much information, I stopped and realized I could not remember the last time I had a headache. I first took FGF-1 up my nose 4 years ago to demonstrate my belief that it is a safe molecule. I went to my medicine cabinet, where I keep my headache medicine, and the medicines had expired two years ago. I cannot remember having had a headache in the last 4 years! On Monday, June 8th at the clinic, a type-2 diabetes patient was getting a redosing of FGF-1. He told me that his data shows he is no longer diabetic; however, the thing he likes the most is that he has not had a migraine headache since his first dosing of FGF- 1 five months ago. Is it real? I do not know, but we should find out.

Can FGF-1 reverse chronic pain? I am excited to find out!

Vika's Section

Our Zhittya team has compiled many of our Parkinson’s disease patient comments over the last 3 years of medical research treatments with FGF-1. Here is a link to those patient comments. I hope you find them as interesting as I do. Zhittya Patient Comments: pd-stories.com

Patient June 17, 2026

Patient Messages

#1) Good afternoon Vika, please feel free to share my testimony with the public.

With a heart full of gratitude, I’m writing to share my deeply personal experience from your clinical trial. What I witnessed in my own body was nothing short of life-changing.

Before the trial, I was afraid to try new foods. I kept my Type 2 diabetes under control with a very strict diet, but any time I stepped outside my normal meals, I would see noticeable spikes in my blood sugar. Since completing Group Four of your trial, and after several months, that fear is gone. My levels have leveled off, things feel much more balanced, and even when I eat more, I’m no longer seeing those big spikes.

I’m truly grateful for this positive change in my life. Thank you from the bottom of my heart for this opportunity to be part of your trial. It has given me back confidence and peace of mind. Sincerely,

Jeff (group 4 participant)

#2) Dear Vika: I have quit my glipizide and I believe it's helping my Sugar reading, it's spiked to around 289 one of my highest readings and it's starting to come back down now. It seems like if I take any meds at all it goes too low.

Really enjoyed our visit so ever thankful for Sam's interaction so we could meet. Thanks for all your wonderful time and the starting of a relationship. Reach out at your convenience. I really appreciate it.

I also believe very much in your procedures. My leg today has less pain and praying it just keeps getting better.

Much care and thank you, Sir

Gary

#3) About 10 years ago or more, I transplanted 2 rose bushes from my mother’s house to my backyard. It’s an old hybrid Rose called Dr. Van Fleet. My grandmother cleaned house for a wealthy woman who had beautiful gardens and shared her perennials with my grandmother (who had a beautiful yard filled with flowers). My mom transplanted a couple of the beautiful pink rose bushes from her mother’s garden to her yard. I always thought they were the best smelling roses ever. After I started growing them in my garden, they never seemed to have any scent. I figured it must be my soil that didn’t have the right nutrients for the roses to have that beautiful scent. Today is the first day this year that I noticed the roses starting to bloom. I sniffed one, and it smells wonderful. Turns out it wasn’t the soil missing something, it was me.

Thanks to FGF-1 I can smell the roses again. I wish I could send the scent to you all, but here’s a picture. I hope the rest of you can smell the roses again \<3 💐

Cross-Border Medical Tourism

Cross-Border Medical Tourism services are for people who want to be considered for Zhittya's future clinical trials or current medical research studies. Cross-Border is now arranging medical tourism to treat Parkinson's disease patients, stroke recovery, type-2 diabetes patients and soon I hope chronic pain in Las Vegas.

Cross-Border is working on filling the Las Vegas medical research studies (intranasal FGF-1 for Parkinson's disease and type-2 diabetes, and more) on the following dates:

Cohort #48: June 23 – 25, 2026

Cohort #49: July 27 – 29, 2026

Cohort #50: August 24 – 26, 2026

Cohort #51: Sept 28 – 30, 2026 To be considered for a cohort, please contact Sam Cross at Cross-Border Medical:

• Email: Sam.crossbordermedical@gmail.com
• Phone: 714-393-8605 If you are also interested in participating in a functional MRI brain scan study at Washington University in St. Louis, please let Sam know. There are a finite number of imaging slots. These studies will examine brain blood flow before and after FGF-1 treatment. ________________________________________________ Upcoming Events:

June 23–29: Washington DC

Dan & Vika will be there and please email me at: dan333@aol.com if there is a reason to meet.

July 9–11: FreedomFest, Las Vegas, NV Caesars Palace, Paradise, Nevada

Zhittya will be making a main stage presentation on Zhittya's medicines.

July 10, 2026: Zhittya is sponsoring a dinner on "Freedom to Try Medical Innovations." I hope we will have 500 attendees, and I will be presenting on Medical Breakthroughs resulting from the Freedom to Try. We also hope to have a noted VIP guest speaker addressing this important topic.

FreedomFest ticket link: http://freedomfest.swoogo.com/zhittya2026

July 20–22: MoneyShow Las Vegas Caesars Palace, Paradise, Nevada

Topic: Breakthrough biotech medicine for treating the cause of death of 65% of all adults.

July 22–25: Caribbean Cardiac Society 39th Annual Cardiology Conference Atlantis, Paradise Island, Bahamas

Zhittya will present on its heart medicine for treating small vessel heart disease. Last year, this conference had about 350 attendees from around the world. It is my hope that we can enlighten hundreds of cardiologists about a new treatment option for their no-option heart patients.

August 26–28: MoneyShow San Francisco Fairmont Hotel, San Francisco, California

Topic: Breakthrough biotech medicine for treating the cause of death of 65% of all adults. Conclusion by Dan Montano:

Life is an interesting journey for all of us. Every month has its problems, its rewards, its frustrations, and its joys. I have been on this journey to develop FGF-1 as a medical treatment for 28 years. I have no doubts FGF-1 can grow new blood vessels in the heart to treat the #1 cause of death in the world: heart disease. I have no doubt FGF-1 can enhance blood flow in the brain to treat Parkinson’s disease, stroke, dementia, Alzheimer’s disease, and more. I believe (but still do not know for sure) that FGF-1 can rejuvenate glucose-sensing neurons in the brain to reverse type-2 diabetes. And now, since June 1st, it has been revealed that FGF- 1 could rejuvenate nerve cells and perhaps reduce pain for maybe a billion people worldwide. Pain is now, it is present, and most people do not like it. Since June 1, 2026 (about 16 days ago), my mind has been investigating whether FGF-1 can reduce chronic pain. I am so excited that the answer may be that FGF-1 can. Yes, it might just be!

Since the last Monthly Update, the information we are getting back from our patients has been amazing. Other diseases, such as type-1 diabetes, I now believe we might be able to treat. Fatty liver disease: I believe we might be able to treat this condition. And the list is growing on the number of disorders FGF-1 may be able to treat. There are amazing possibilities in front of us, and I believe chronic pain is the biggest of them all. Equally exciting is that we may already be generating data from our ongoing Medical Research Studies that support our new protocols.

I seldom sleep past 3 AM. I go to sleep wondering about so much, and my brain wakes up long before my body does. Every morning, I am like a child on Christmas morning, I am excited that I have presents waiting for me. I get up and start researching or planning or calling people to move this journey along. Next month, July, I will turn 78 years old. I do not have time to waste on meaningless tasks. I look back at all the waste of the last 28 years. Time wasted as I listened to the experts who got paid by the hour, not by the accomplishment. Pain is horrible and wasted time is the enemy. Please, if you have any ideas, share them with us. Each of you is blessed with a unique genius, and you can look and see if we missed something. I have been working on FGF-1 for 28 years. Dr. Jacobs, Zhittya’s President, was one of the people who discovered FGF-1 over 40 years ago. Yet only two weeks ago, none of us were thinking about using FGF-1 to treat the one billion people suffering with chronic pain. What else are we missing?

As always, I thank you for your support and your guidance.

I am blessed and pray that you are also blessed!

God bless you and thank you all.

Dan Montano CEO, Zhittya Genesis Medicine 8683 W. Sahara Ave., Suite 280 Las Vegas, NV 89117 (USA) 702-802-8373 zgm.care

[mailto:dan333@aol.com](mailto:dan333@aol.com)

<https://freedomfest.swoogo.com/vegas2026>

<https://freedomfest.swoogo.com/zhittya2026>

[mailto:sergiy@zhittyamedicine.com](mailto:sergiy@zhittyamedicine.com)

<https://zgm.care/pain>

<https://cure-wounds.com/>

<http://pd-stories.com/>

[mailto:dan333@aol.com](mailto:dan333@aol.com)

<http://freedomfest.swoogo.com/zhittya2026>

<https://zgm.care/>